Acarbose
≈ 6 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
{{Infobox drug | Watchedfields = changed | verifiedrevid = 477237664 | image = Haworth projection of acarbose.svg | image_class = skin-invert-image | alt = Haworth projection of acarbose | width = 300 | image2 = Acarbose-3D-balls.png | image_class2 = bg-transparent | alt2 = Ball-and-stick model of the acarbose molecule | width2 = 200 | tradename = Glucobay, Precose, Prandase | Drugs.com = | MedlinePlus = a696015 | DailyMedID = Acarbose | pregnancy_AU = B3 | routes_of_administration = By mouth | ATC_prefix = A10 | ATC_suffix = BF01 | ATC_supplemental = | legal_UK = POM | legal_US = Rx-only | bioavailability = Extremely low | protein_bound = | metabolism = Gastrointestinal tract | elimination_half-life = 2 hours | excretion = Kidney (less than 2%) | CAS_number_Ref = | CAS_number = 56180-94-0 | PubChem = 444254 | IUPHAR_ligand = 6791 | DrugBank_Ref = | DrugBank = DB00284 | ChemSpiderID_Ref = | ChemSpiderID = 392239 | UNII_Ref = | UNII = T58MSI464G | KEGG_Ref = | KEGG = D00216 | ChEMBL_Ref = | ChEMBL = 1566 | synonyms = (2R,3R,4R,5S,6R)-5- {[(2R,3R,4R,5S,6R)-5- {[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl- 5- {[(1S,4R,5S,6S)-4,5,6-trihydroxy-3- (hydroxymethyl)cyclohex-2-en-1-yl]amino} tetrahydro-2H-pyran-2-yl]oxy}-3,4-dihydroxy- 6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}- 6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol | IUPAC_name = O-4,6-Dideoxy-4- -α- D -glucopyranosyl-(1→4)-O…
{{Infobox drug | Watchedfields = changed | verifiedrevid = 477237664 | image = Haworth projection of acarbose.svg | image_class = skin-invert-image | alt = Haworth projection of acarbose | width = 300 | image2 = Acarbose-3D-balls.png | image_class2 = bg-transparent | alt2 = Ball-and-stick model of the acarbose molecule | width2 = 200 | tradename = Glucobay, Precose, Prandase | Drugs.com = | MedlinePlus = a696015 | DailyMedID = Acarbose | pregnancy_AU = B3 | routes_of_administration = By mouth | ATC_prefix = A10 | ATC_suffix = BF01 | ATC_supplemental = | legal_UK = POM | legal_US = Rx-only | bioavailability = Extremely low | protein_bound = | metabolism = Gastrointestinal tract | elimination_half-life = 2 hours | excretion = Kidney (less than 2%) | CAS_number_Ref = | CAS_number = 56180-94-0 | PubChem = 444254 | IUPHAR_ligand = 6791 | DrugBank_Ref = | DrugBank = DB00284 | ChemSpiderID_Ref = | ChemSpiderID = 392239 | UNII_Ref = | UNII = T58MSI464G | KEGG_Ref = | KEGG = D00216 | ChEMBL_Ref = | ChEMBL = 1566 | synonyms = (2R,3R,4R,5S,6R)-5- {[(2R,3R,4R,5S,6R)-5- {[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl- 5- {[(1S,4R,5S,6S)-4,5,6-trihydroxy-3- (hydroxymethyl)cyclohex-2-en-1-yl]amino} tetrahydro-2H-pyran-2-yl]oxy}-3,4-dihydroxy- 6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}- 6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol | IUPAC_name = O-4,6-Dideoxy-4- -α- D -glucopyranosyl-(1→4)-O-α- D -glucopyranosyl-(1→4)- D -glucopyranose | C = 25 | H = 43 | N = 1 | O = 18 | smiles = O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@H]4O[C@@H]([C@@H](O[C@H]3O[C@H](C)[C@@H](N[C@H]2/C=C(/CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]3O)[C@H](O)[C@H]4O)CO | StdInChI_Ref = | StdInChI = 1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-/m1/s1 | StdInChIKey_Ref = | StdInChIKey = XUFXOAAUWZOOIT-SXARVLRPSA-N }} Acarbose (INN) is an anti-diabetic drug used to treat diabetes mellitus type 2 and (in some countries), prediabetes. It is sold in Europe and China as Glucobay (Bayer AG), in North America as Precose (Bayer Pharmaceuticals), and in Canada as Prandase (Bayer AG). Acarbose is a starch blocker that works by inhibiting alpha glucosidase, an intestinal enzyme that releases glucose from larger carbohydrates such as starch and sucrose. It is composed of an acarviosin moiety with a maltose at the reducing terminus. It can be degraded by gut bacteria. Acarbose is inexpensive and popular in China, but not in the U.S. One physician explains that U.S. use is limited, because it is not potent enough to offset side effects of diarrhea and flatulence. However, a large 2013 study reported that "acarbose is effective, safe and well tolerated in a large cohort of Asian patients with type 2 diabetes." One possible explanation for the differing claims is that acarbose is significantly more effective in patients eating a relatively high-starch, Eastern diet.
Combination therapy
The combination of acarbose with metformin results in greater reductions of HbA1c, fasting blood glucose and post-prandial glucose than either agent alone.
Adverse effects
Since acarbose prevents the degradation of complex carbohydrates into glucose, some carbohydrate will remain in the intestine and be delivered to the colon. In the colon, bacteria digest (ferment) the complex carbohydrates, causing gastrointestinal side-effects such as flatulence (78% of patients) and diarrhea (14% of patients). Since these effects are dose-related, in general it is advised to start with a low dose and gradually increase the dose to the desired amount. One study found that gastrointestinal side effects decreased significantly (from 50% to 15%) over 24 weeks, even on constant dosing. Sucrose is more likely to trigger GI side effects compared to starch. Acarbose is associated with very rare elevated transaminases (19 out of 500,000). Even rarer cases of hepatitis has been reported with acarbose use. It usually goes away when the medicine is stopped. Liver enzymes should be checked before and during use of this medicine as a precaution. A 2016 meta-analysis confirms that alpha-glucosidase inhibitors, including acarbose, have a statistically significant link to elevated transaminase levels.
Mechanism of action
Acarbose inhibits enzymes (glycoside hydrolases) needed to digest carbohydrates, specifically, alpha-glucosidase enzymes in the brush border of the small intestines, and pancreatic alpha-amylase. It locks up the enzymes by mimicking the transition state of the substrate with its amine linkage. However, bacterial alpha-amylases from gut microbiome are able to degrade acarbose. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, whereas the membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drug therapies is to decrease current blood glucose levels; the long-term effect is a reduction in HbA 1c level.
Natural distribution
In nature, acarbose is synthesized by soil bacteria Actinoplanes sp through its precursor valienamine.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1369016458 under CC BY-SA 4.0; modifications have been made.